BioNTech / Pfizer vaccine proves itself in “real world”


Tel Aviv.

According to the Israeli Ministry of Health, the corona vaccine from BioNTech / Pfizer prevents around 99 percent serious illnesses or deaths after the second vaccination. That emerges from data that the ministry published on Sunday. Israel began administering the vaccine on December 19.  The  dates last until February 13th.
Corona disease was prevented by 95.8 percent, the occurrence of symptoms such as fever and breathing difficulties by 98 percent and hospital stays, serious illnesses and death by around 99 percent. © The  degree of effectiveness of the vaccine was measured 14 days after the second vaccination. ©

 The  ministry compared the incidence and death rates between those who had been vaccinated and those who were not.

Health ministry director general Professor Chesi Levy said the data showed a significant decrease in disease and death rates. “We are the first country in the world that was able to demonstrate the effectiveness of the corona vaccine in the real clinical world.”

Israel: pioneer in corona vaccination

Pfizer recommends vaccination intervals of three to four weeks. Previous analyzes had shown the vaccine to be 95 percent effective in preventing symptomatic infections one week after the second vaccination. This means that 95 percent fewer diseases occurred among the subjects in the vaccinated group than among those in a control group.

 The  vaccination campaign in Israel is very advanced compared to other countries. ©

 The  country with its 9.3 million inhabitants is considered a pioneer. ©

 The  government plans to offer vaccinations to all residents of the country who are older than 16 years by the end of March.

Protected from infection after vaccination?

To what extent the corona vaccine from BioNTech / Pfizer also protects against infection with the pathogen remains unclear. So far, there has only been knowledge to what extent the agent protects against diseases. ©

 The  active ingredient is “highly effective” in preventing infections with Sars-CoV-2, according to the manuscript for the study by the two manufacturers together with the Israeli Ministry of Health. However, the study authors also write that their approach could lead to the effect of vaccination on infections being overestimated.

 The  study results are difficult to assess. ©

 The  manuscript was leaked to Israeli journalists from the internet portal “ynet” and has not been officially published, neither on a preprint server nor in a specialist journal examined by experts. It is available to the German Press Agency. BioNTech did not want to comment on the document when asked on Sunday. ©

 The  Ministry of Health did not comment either.

© The  data should be treated with caution”

Israel’s Corona representative, Nachman Asch, told the army broadcaster on Sunday that the data should be treated with caution: “We don’t yet know enough about infections, that’s the big unknown.” It is clear that the vaccination prevents serious disease progression. “But I don’t know to what extent it prevents vaccinated people from carrying and passing on the virus.” He hopes that more will be found out about it in the coming weeks. (dpa)

[ source link ]–417292.html

BioNTech Pfizer vaccine proves real world


Please enter your comment!
Please enter your name here